A 48-year-old man with biopsy-confirmed pemphigus vulgaris (anti-desmoglein 3 positive) presents with extensive oral erosions and scattered blisters on the trunk and flexures. He has been on prednisolone 1 mg/kg/day for 4 weeks with modest clinical improvement but persistent new blister formation. What is the most appropriate next step in management?

Explanation

## Management of Corticosteroid-Inadequate Pemphigus Vulgaris This patient has **inadequate response** to standard-dose corticosteroid monotherapy (persistent new blister formation after 4 weeks at 1 mg/kg/day). The next step is to introduce a **steroid-sparing immunosuppressive agent** rather than further escalate corticosteroids alone. ### Why Steroid-Sparing Agents Are Indicated **Key Point:** Steroid-sparing agents (azathioprine, mycophenolate mofetil, or rituximab) are added when: 1. Inadequate response to standard corticosteroid doses (persistent disease activity) 2. Need to minimize long-term corticosteroid exposure and side effects 3. Corticosteroid dependence (flares on tapering) **High-Yield:** First-line steroid-sparing agents for PV: - **Azathioprine** — 1–2 mg/kg/day; onset 6–8 weeks; monitor CBC and LFTs - **Mycophenolate mofetil (MMF)** — 1–3 g/day in divided doses; onset 4–6 weeks; generally better tolerated than AZA - **Rituximab** — reserved for severe, refractory cases; anti-CD20 monoclonal antibody targeting B cells ### Mechanism of Benefit Steroid-sparing agents: - Reduce circulating anti-desmoglein antibodies - Allow gradual corticosteroid tapering (reducing cumulative dose and toxicity) - Achieve disease remission or low disease activity ### Clinical Pearl Combination therapy (corticosteroid + steroid-sparing agent) is superior to corticosteroid monotherapy in preventing relapse and reducing long-term morbidity. The combination allows lower maintenance corticosteroid doses and better disease control. ### Management Algorithm ```mermaid flowchart TD A["Biopsy-confirmed PV"]:::outcome --> B["Start prednisolone 1 mg/kg/day"]:::action B --> C{"Response at 4 weeks?"}:::decision C -->|"Good response"| D["Slow taper; monitor for flare"]:::action C -->|"Inadequate response"| E["Add steroid-sparing agent<br/>AZA or MMF"]:::action E --> F["Gradual corticosteroid tapering"]:::action F --> G["Target: remission or low activity"]:::outcome C -->|"Severe/refractory"| H["Consider rituximab"]:::action ``` **Rationale for Not Escalating Corticosteroids Alone:** - Increasing to 1.5 mg/kg/day increases infection risk, metabolic complications, and osteoporosis without addressing the underlying immune dysregulation - Steroid-sparing agents target the B cell and antibody production directly [cite:Harrison 21e Ch 322; KD Tripathi 8e Ch 62]